Preventing complications after pancreatic surgery with a drug bundle
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests whether giving a combination of three treatments—hydrocortisone (a steroid), octreotide (a drug that reduces digestive fluids), and a tissue patch—before and during pancreatic surgery can help prevent complications. It is for people with a very small pancreatic duct (3 mm or less) who are scheduled for pancreatic surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are scheduled for elective pancreatic surgery (Whipple procedure) for any reason, whether by keyhole or open surgery.
- Your pancreatic duct is 3 millimeters or smaller on a recent CT or MRI scan.
- You are 18 years of age or older.
- You are not pregnant or breastfeeding, and have no known allergy to hydrocortisone or octreotide.
- You do not have a current systemic fungal infection, and are not taking certain medications that interact with hydrocortisone or octreotide.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving two already-approved chemotherapy drugs and radiation before surgery works better for localized pancreatic cancer. It’s meant for people whose cancer looks removable by surgery and who haven’t had prior pancreatic cancer treatment.
This study helps people going for planned pancreatic cancer surgery (with or without chemo beforehand) by focusing on controllable risk factors before the operation. The goal is to improve safety and outcomes after surgery.
This trial tests whether giving a steroid called hydrocortisone before and after surgery to remove part of the pancreas can help patients recover better. It aims to reduce complications and improve outcomes.
This trial tests whether a drug called octreotide microspheres can help prevent a common complication after surgery to remove part of the pancreas. If you are scheduled for this type of surgery, this study may help reduce your risk of developing a leak from the pancreas.
This trial tests a combination of two immunotherapy drugs (durvalumab and oleclumab) given before surgery to people with pancreatic cancer that can be removed. The goal is to see if this treatment helps the immune system fight the cancer better.
This trial studies giving chemo and hydroxychloroquine before surgery for resectable pancreatic cancer. The goal is to shrink the tumor and improve the chances of successful removal.
Hear when a new IPMN, Pancreatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.